GLPG 4059
Alternative Names: GLPG-4059; GPLG4059Latest Information Update: 12 May 2021
At a glance
- Originator Galapagos NV
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Metabolic disorders
Most Recent Events
- 06 May 2021 Discontinued - Phase-I for Diabetes mellitus (In volunteers) in Netherlands (unspecified route)
- 06 May 2021 Discontinued - Phase-I for Metabolic disorders (In volunteers) in Netherlands (unspecified route)
- 08 Apr 2021 Galapagos terminates a phase I trial in Metabolic disorders and Diabetes mellitus (In volunteers) in Netherlands since the development of compound has been stopped (PO, Suspension) (NCT04575818)